The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV. A second purpose for this study is to understand how your immune system responds to the study vaccine with the adjuvants. Understanding these differences could be useful in several ways. First, it might help identify people whose disease is likely to respond to the study vaccine with the study adjuvants. Second, the information might be useful in developing other treatments for people whose disease does not respond to the study vaccine with the adjuvants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
91
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Denver, Colorado, United States
Unnamed facility
Orlando, Florida, United States
Unnamed facility
Boston, Massachusetts, United States
Unnamed facility
Austin, Texas, United States
Unnamed facility
Dallas, Texas, United States
Unnamed facility
Berlin, Germany
Unnamed facility
Cologne, Germany
Unnamed facility
Frankfurt, Germany
Unnamed facility
Hamburg, Germany
...and 3 more locations
To evaluate the safety and tolerability of intramuscular administration of HIV-1 gag DNA vaccine (total of three doses) in individuals on stable HAART
intramuscular administration of HIV-1 gag DNA vaccine when administered with increasing dosage levels of IL-12 DNA following each vaccine dose (total of three doses) in individuals on stable HAART
intramuscular administration of HIV-1 gag DNA vaccine when administered with increasing dosage levels of IL-15 DNA following each vaccine dose (total of three doses) in individuals on stable HAART
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.